Making the Case for Early Biologics in Lupus Save

A new diagnosis of systemic lupus erythematosus (SLE) can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and long-term outcomes. Several abstracts presented at ACR 2026 provide new insights into the potential benefits of early biologic treatment.

Abstract 1211 presented interim findings from BE-EARLY, an ongoing prospective, open-label phase 4 study evaluating belimumab in patients diagnosed with SLE within the past two years. Early results are promising. By week 26, 30% of patients achieved lupus low disease activity state (LLDAS), 93% were receiving ≤7.5 mg/day of prednisone-equivalent glucocorticoids following protocol-mandated tapering, and 62% of patients with severe baseline fatigue achieved a clinically meaningful improvement in FACIT-Fatigue scores.

Similarly, Abstract 1213 presented findings from RELIABLE, an observational study examining early versus later belimumab initiation. At month 12, a higher proportion of patients receiving early versus non-early belimumab achieved LLDAS (72.6% vs 52.9%) and DORIS remission (48.4% vs 24.0%), with both differences statistically significant. Glucocorticoid use also decreased, with 81% of the overall cohort achieving doses ≤7.5 mg/day and 67.7% achieving ≤5 mg/day.

But what do these treatment targets mean for patients beyond disease activity?

Abstract 2253 examined the relationship between achieving LLDAS or DORIS remission and work productivity. Patients achieving LLDAS reported lower presenteeism (21% vs 38%), overall work impairment (23% vs 40%), and estimated annual income losses related to work impairment ($11,023 vs $22,105; *P* < 0.001). Similar numerical trends were observed among patients achieving DORIS remission, although differences in work productivity did not reach statistical significance.

Together, these findings strengthen the case for considering biologic therapy earlier in lupus. 

In my practice, I often begin these conversations early, with the goals of improving disease control and minimizing glucocorticoid exposure. The work-productivity findings also underscore why achieving treatment targets matters beyond the clinic. While promising, these studies leave an important question unanswered: does earlier biologic initiation lead to better long-term outcomes than later initiation? Longer-term, controlled comparisons will help clarify which patients stand to benefit most.